IPO · SENORES

Senores Pharmaceuticals IPO listing gain & performance.

Issue price, subscription, listing day and what the share did after, from NSE data. Updated every evening.

· data for the trading session of Wed 18 Nov 2026

Issue price₹391.00₹372 to ₹391
Listing gain+53.5%at the opening price
Since the IPO+179.4%₹1,092.60 on 18 Nov
Subscribed93.7×times in total

Senores Pharmaceuticals IPO in brief

Written from NSE’s data, as of 18 Nov 2026.

Senores Pharmaceuticals came to the market at ₹391.00 a share (price band ₹372 to ₹391), with bidding open from 20 December to 24 December 2024. It listed on NSE on Monday, 30 December 2024, opening at ₹600.00, a gain of 53.5% on the issue price, and closed the first day +42.5% from the issue price after trading between +37.8% and +55.9%. 45% of the first day’s traded shares were taken for delivery.

The issue was subscribed 93.7× in total, institutions (QIB) 94.7×, HNIs (NII) 96.3×, retail investors 90.5×. Across the 91 IPOs subscribed 50× or more, the median listing gain was +26.6%.

Its listing gain beat 93% of the 227 main-board IPOs since October 2024, where the median was +7.6%. 1 year after listing it was +110.3% from the issue price and +47.6% from the first-day close, while NIFTY 50 moved +10.5% over the same days. Its highest price so far was 309% above the issue price (24 Aug 2026) and its lowest 11% above it (13 Jan 2025); it closed below the issue price on 0% of the days since listing.

Share price since listing

Daily closes, adjusted for later splits and bonuses. The dashed line is the IPO price.

IPO ₹39130 Dec 202418 Nov 2026₹1,093

Subscription

Times subscribed by investor group, NSE + BSE bids as reported by NSE.

Qualified institutions (QIB)94.7×
Non-institutional (NII / HNI)96.3×
NII, bids above ₹10 lakh93.5×
NII, ₹2–10 lakh102×
Retail investors90.5×
Employees20.2×
Total93.7×

For comparison, the median main-board IPO since Oct 2024 was subscribed 28.4× in total.

Listing day

Monday 30 December 2024.

Open+53.5%vs issue price
High / low+56% / +38%vs issue price
Close+42.5%vs issue price
Delivery45%₹824 Cr traded

Returns after listing

Against the issue price and the first-day close, with NIFTY 50 and the median IPO for comparison.

After listingFrom issue priceFrom first-day closeNIFTY 50Median IPO (from issue)
1 week6 Jan 2025+41.4%-0.7%-0.1%+8.0%
1 month28 Jan 2025+28.5%-9.8%-2.9%+9.4%
3 months28 Mar 2025+45.9%+2.4%-0.5%+10.3%
6 months2 Jul 2025+48.6%+4.3%+7.6%+8.0%
1 year31 Dec 2025+110.3%+47.6%+10.5%-8.9%

IPO details

From NSE’s issue page.

Company
Senores Pharmaceuticals
NSE symbol
SENORES
Board
Main board
Industry
Pharmaceuticals
Bidding
20 Dec – 24 Dec 2024
Price band
₹372 to ₹391
Issue price
₹391.00
Issue size
Initial Public Offer of Fresh Issue upto 5,000 million and Offer for Sale Up to 21,00,000 Equity Shares (including Anchor Allocation of 66,65,725 Equity Shares)
Bid lot
38 Equity Shares and in multiples thereof
Listing date
30 December 2024
ISIN
INE0RB801010

Senores Pharmaceuticals share price, delivery & results →How all IPOs did after listing →IPO calendar →

Questions

What was the listing gain of the Senores Pharmaceuticals IPO?
Senores Pharmaceuticals listed on 30 December 2024 and opened +53.5% against its issue price of ₹391.00; it closed the first day +42.5% from the issue price.
What is the Senores Pharmaceuticals share price now against the IPO price?
At the close of 18 November 2026, Senores Pharmaceuticals was at ₹1,092.60, +179.4% from the IPO price of ₹391.00.
How many times was the Senores Pharmaceuticals IPO subscribed?
Senores Pharmaceuticals’s IPO was subscribed 93.7× in total; QIB 94.7×; NII 96.3×; retail 90.5× (NSE + BSE bids, as reported by NSE).
When was the Senores Pharmaceuticals IPO open?
Bidding ran from 20 December to 24 December 2024 at a price band of ₹372 to ₹391; the shares listed on 30 December 2024.

From NSE’s issue list and daily price files (adjusted for later splits and bonuses), and subscription as NSE reports it (NSE + BSE bids). Past IPOs do not predict future ones. Information for learning, not investment advice; ChartMine is not a SEBI-registered adviser.

See it live on your chart.ChartMine for TradingView.